Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed at $1.22 down -37.44% from its previous closing price of $1.95. In other words, the price has decreased by -$37.44 from its previous closing price. On the day, 20.96 million shares were traded. LXRX stock price reached its highest trading level at $1.38 during the session, while it also had its lowest trading level at $1.16.
Ratios:
For a deeper understanding of Lexicon Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.49 and its Current Ratio is at 11.51. In the meantime, Its Debt-to-Equity ratio is 0.44 whereas as Long-Term Debt/Eq ratio is at 0.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 17, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On April 30, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $5.
On March 07, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $3.Jefferies initiated its Hold rating on March 07, 2023, with a $3 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 ’24 when COATS LONNEL bought 300,000 shares for $1.60 per share.
COATS LONNEL bought 90,000 shares of LXRX for $94,797 on Nov 16 ’23. The Chief Executive Officer now owns 914,359 shares after completing the transaction at $1.05 per share. On Nov 10 ’23, another insider, COATS LONNEL, who serves as the Chief Executive Officer of the company, bought 10,000 shares for $1.01 each. As a result, the insider paid 10,100 and bolstered with 824,359 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 441020256 and an Enterprise Value of 236732592. For the stock, the TTM Price-to-Sale (P/S) ratio is 75.80 while its Price-to-Book (P/B) ratio in mrq is 1.84. Its current Enterprise Value per Revenue stands at 65.019 whereas that against EBITDA is -1.205.
Stock Price History:
Over the past 52 weeks, LXRX has reached a high of $3.73, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is -28.92%, while the 200-Day Moving Average is calculated to be -36.27%.
Shares Statistics:
For the past three months, LXRX has traded an average of 2.80M shares per day and 4907310 over the past ten days. A total of 361.49M shares are outstanding, with a floating share count of 349.07M. Insiders hold about 3.44% of the company’s shares, while institutions hold 76.93% stake in the company. Shares short for LXRX as of 1728950400 were 27650080 with a Short Ratio of 9.88, compared to 1726185600 on 26627093. Therefore, it implies a Short% of Shares Outstanding of 27650080 and a Short% of Float of 16.97.
